SLEEP DISTURBANCE IN PARKINSON'S DISEASE AND PARKINSON-LIKE CONDITIONS
RELEASE DATE: June 2, 2003
PA NUMBER: PAS-03-131
EXPIRATION DATE: September 30, 2006
National Institute of Neurological Disorders and Stroke (NINDS)
(http://www.ninds.nih.gov)
National Heart, Lung, and Blood Institute (NHLBI)
(http://www.nhlbi.nih.gov)
CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER(S): 93.853, 93.233, 93.837,
93.838, 93.839
THIS PA CONTAINS THE FOLLOWING INFORMATION
o Purpose of the PA
o Research Objectives
o Mechanisms of Support
o Funds Available
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Where to Send Inquiries
o Submitting an Application
o Peer Review Process
o Review Criteria
o Award Criteria
o Required Federal Citations
PURPOSE OF THIS PA
This is a program announcement (PA) with set-aside funds. The PA is
designed to stimulate and support research on sleep disorders in
Parkinson's disease (PD) and Parkinson's related neurological conditions
(PRNC). Support will be for research on PD and PRNC patients as well as
patients in appropriate comparison groups and/or healthy control subjects.
Responsive applications could deal with the following areas: natural
history of symptoms studies, mechanistic studies of the sleep disturbances
in PD and PRNC, associated sleep disorders such as Restless Legs Syndrome
(RLS) and sleep-disordered breathing (SDB), and studies of the sleep-
related effects of pharmacotherapies for PD and PRNC. The timing and scope
of this PA are predicated on recent research and clinical findings
indicating promising new directions for the diagnosis and care of patients
with PD and PRNC.
RESEARCH OBJECTIVES
Sleep disturbances affect the overwhelming majority of PD patients during the
course of their illness. This has significant adverse effects upon quality
of life and, in some cases, safety on the road and in the workplace.
Medications prescribed for PD may also affect sleep and wakefulness. Drugs
that act on dopamine systems can cause or exacerbate underlying daytime
sleepiness, and paradoxically, can improve or worsen the quality of nighttime
sleep. These problems also extend into the larger population of patients
with neurodegenerative disorders that exhibit parkinsonian features
collectively referred to in this PA as Parkinson's related neurological
conditions (PRNC) and include but are not limited to: Diffuse-Lewy body (DLB)
disease, multiple systems atrophy (MSA), and RLS. The wide spectrum and
ubiquity of disordered sleep and decrements in daytime arousal in PD and PRNC
patients has prompted re-examination of their 24-hour patterns of wake/sleep.
Key findings in patients with these conditions are: disrupted nocturnal
sleep, greater prevalence of periodic leg movements (PLM) and obstructive and
central sleep apnea relative to controls, sleepiness irrespective of their
drug therapy, and REM sleep behavior disorder (RBD) as an early
manifestation. In RBD, the normal muscle paralysis that occurs during REM
sleep is disrupted so that patients retain muscle tone allowing them to "act
out" emotionally laden and often violent dreams. RBD, therefore, not only
disturbs the sleep of the bed partner, but also can cause injury to patients
and others nearby.
The natural history of sleep disturbances in PD and PRNC remains unknown, as
well as the relationship of sleep disturbances to frequent comorbid
conditions such as depression and dementia. Clinical experience and
increasing evidence from animal studies and animal-models of these disorders
consistently indicate that altered function of dopamine neurons may account
for not only the daytime motor symptoms of PD, but also co-morbid
disturbances in maintenance of a normal sleep-wake cycle. This PA is
intended to encourage and support research on PD patients and appropriate
comparison groups, possibly including healthy control subjects. Key
objectives of this PA include: (1) a better understanding of the
pathophysiological basis of sleep disturbances in treatment-na ve or drug-
free PD and PRNC patients, (2) the extent and characteristics of effects on
sleep and wakefulness produced by available pharmacotherapies for PD and
PRNC, and (3) identification of interventions to reduce the burden of sleep-
related symptoms on PD and PRNC patients. Resulting information will improve
recognition, diagnosis and treatment of these disorders. Of particular
relevance will be studies of mechanisms by which dopamine affects arousal and
physiological measures of sleep, investigations of natural history of
disturbed sleep in PD, interactions of medical and surgical treatment of PD
to disturbed sleep, and neuroimaging or neuropathological characterization of
patients with well documented PD-related sleep disturbances. Studies of the
relationship between sleep disturbances and commonly prescribed medications
that interact either directly or indirectly with dopaminergic systems will
also be encouraged. New research has described a previously unknown
mesothalamic dopamine system in which the thalamus receives dopaminergic
inputs from the same cells as those that degenerate in Parkinson's disease.
Another study has found dopamine neurons in the dorsal raphe, a brainstem
area rich in serotonin and considered important for the regulation of sleep.
These findings suggest heretofore unrecognized mechanisms that may be
relevant to sleep disorders in PD. Supportable clinical studies will include
patients with other disorders associated with defects in dopaminergic
transmission (e.g., DLB, MSA, PLM, and RLS. It is important to better
understand the mechanisms by which dopaminergic drugs used outside the realm
of PD so profoundly affect sleep and motor function. Such drugs include, but
are not limited to, amphetamines and phenothiazines. Since the motor and
sleep mechanisms affected by PD seem to interact with other transmitter
systems, such as GABA, norepinephrine, serotonin, acetylcholine, histamine,
etc., this PA is likely to reveal new understanding of the defects underlying
PD as well as new therapeutic approaches.
This PA is NOT intended to support clinical trials whose primary aim is to
evaluate treatment efficacy for the motor symptoms of PD or PRNC. Examples
of research that would be considered relevant to this announcement include,
but are not limited to, the following:
o Studies on the natural history of sleep and wakefulness symptoms in PD and
PRNC.
o Studies to elucidate mechanisms by which these conditions affect sleep and
wakefulness.
o Studies on the inter-relationship between disturbed sleep and impaired
wakefulness. For example, to what extent, in these patient groups, do sleep
disturbances cause impaired waking function? To what extent are disturbed
sleep and impaired wakefulness joint manifestations of the same CNS defect?
o Studies to define possible sub-populations of PD and PRNC appropriate for
adjuvant pharmacotherapy or modified primary pharmacotherapy, aimed at
reducing problems with sleep and/or wakefulness.
o Studies to define the extent to which SDB or other sleep disorders
contribute to impaired wakefulness in PD and PRNC, including studies of upper
airway motorneuron function.
o Studies to elucidate abnormalities in the neurobiology of hypocretin and
leptin associated with PD or PRNC and leading to altered chemosensitivity or
increased upper airway resistance during sleep.
o Preliminary/pilot studies to elucidate mechanisms by which
pharmacotherapies for these conditions affect sleep and wakefulness.
o Preliminary/pilot studies to identify promising interventions to improve
the sleep and wakefulness of PD and PRNC patients.
o Preliminary/pilot studies to optimize the intervention strategy (e.g.,
dose, duration, frequency of dosing). For example, studies designed to
investigate dose-concentration, dose-response, or concentration-response
relationships may contribute to optimal dosage selection to minimize adverse
effects on sleep and wakefulness.
o Preliminary/pilot studies to assess the appropriate delivery system or
parameter settings of an electronic device or surgical technique.
o Preliminary/pilot studies to assess the safety and tolerability at various
doses or concentrations of a specific intervention.
o Preliminary/pilot studies designed to explore pharmacokinetic and
pharmacodynamic relationships.
Prospective applicants should be aware that, in some cases, especially in
connection with protocol and experimental design, there may be convergent
objectives between the present PA and the PA entitled, "PILOT STUDIES FOR
CLINICAL TRIALS IN NEUROLOGICAL DISORDERS". See:
http://grants.nih.gov/grants/guide/pa-files/PAR-01-119.html. It is strongly
encouraged that prospective applicants, who are considering a response to the
present PA that entails pharmacotherpeutic intervention, discuss the proposal
with the Clinical Trials Group at NINDS prior to the submission of the
application (contact below).
Dr. Scott Janis
Clinical Trials Group
National Institute of Neurological Disorders and Stroke
Neuroscience Center, Room 2210
6001 Executive Blvd
Bethesda, MD 20892
301-496-9135 (phone)
janisS@ninds.nih.gov
MECHANISMS OF SUPPORT
This PA will use the NIH research project grant (R01) and the program project
grant (P01) award mechanisms. As an applicant, you will be solely
responsible for planning, directing, and executing the proposed project.
This PA uses just-in-time concepts. It also uses the modular as well as the
non-modular budgeting formats (see
http://grants.nih.gov/grants/funding/modular/modular.htm). Specifically, if
you are submitting an application with direct costs in each year of $250,000
or less, use the modular format. Otherwise follow the instructions for non-
modular research grant applications. This program does not require cost
sharing as defined in the current NIH Grants Policy Statement at
http://grants.nih.gov/grants/policy/nihgps_2001/part_i_1.htm.
FUNDS AVAILABLE
NINDS has set aside $1,500,000 in total costs to fund applications that do
not score within the NINDS payline (see NINDS Funding Strategy
http://www.ninds.nih.gov/funding/ninds_funding_strategy.htm). The amount and
timing of awards paid from set aside funds will depend on the overall
scientific merit of the applications and the availability of funds throughout
the duration of this solicitation (3 years). NHLBI anticipates funding 1-3
applications with sufficient merit at levels of support similar to NINDS.
Assignment will be based on customary NIH referral guidelines. Although the
National Institute on Aging (NIA) is not a co-sponsor of this PA, it is
interested in the support of research on the disorders of sleep that afflict
the older population. As such, the NIA would be interested in meritorious
applications submitted in response to this announcement that are relevant to
its mission and competitive within its funding plan.
ELIGIBLE INSTITUTIONS
You may submit (an) application(s) if your institution has any of the
following characteristics:
o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges, hospitals,
and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Domestic or foreign
o Faith-based or community-based organizations
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always
encouraged to apply for NIH programs.
WHERE TO SEND INQUIRIES
We encourage your inquiries concerning this PA and welcome the opportunity to
answer questions from potential applicants. Inquiries may fall into two
areas: scientific/research and financial or grants management issues:
o Direct your questions about scientific/research issues to:
Merrill M. Mitler, Ph.D.
Program Director
Systems and Cognitive Neuroscience
National Institute of Neurological Disorders and Stroke
Neuroscience Center, Room 2116
6001 Executive Blvd
Bethesda, MD 20892
301-496-9964 (phone)
301-402-2060 (fax)
mitlerm@ninds.nih.gov
Carl E. Hunt, M.D.
Director, National Center on Sleep Disorders Research
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, Suite 10038
Bethesda, MD 20892-7920
301-435-0199 (phone)
301-480-3451 (fax)
huntc@nhlbi.nih.gov
o Direct your questions about financial or grants management matters to:
Karen D. Shields
National Institute of Neurological Disorders & Stroke
Senior Grants Management Specialist
6001 Executive Blvd, Suite 3290
Bethesda, Maryland 20892 (Regular Mail)
Rockville, Maryland 20852 (Courier Service)
(301)496-7393 Direct Line
(301)496-9231 Main Line
(301)402-0219 Fax
ks26n@nih.gov
Robert Pike
National Heart, Lung, and Blood Institute
Section Chief, Grants Operations Branch
6701 Rockledge Drive MSC 7926
Bethesda, Maryland 20852
(Courier Service 20817)
301-435-0166
301-480-3310 Fax
piker@nhlbi.nih.gov
SUBMITTING AN APPLICATION
Applications must be prepared using the PHS 398 research grant application
instructions and forms (rev. 5/2001). The PHS 398 is available at
http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive
format. For further assistance contact GrantsInfo, Telephone (301) 435-0714,
Email: GrantsInfo@nih.gov.
APPLICATION RECEIPT DATES: Applications submitted in response to this program
announcement will be accepted at the standard application deadlines, which
are available at http://grants.nih.gov/grants/dates.htm. Application
deadlines are also indicated in the PHS 398 application kit.
SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS: Applications requesting
up to $250,000 per year in direct costs must be submitted in a modular grant
format. The modular grant format simplifies the preparation of the budget in
these applications by limiting the level of budgetary detail. Applicants
request direct costs in $25,000 modules. Section C of the research grant
application instructions for the PHS 398 (rev. 5/2001) at
http://grants.nih.gov/grants/funding/phs398/phs398.html includes step-by-step
guidance for preparing modular grants. Additional information on modular
grants is available at
http://grants.nih.gov/grants/funding/modular/modular.htm.
SPECIFIC INSTRUCTIONS FOR APPLICATIONS REQUESTING $500,000 OR MORE PER YEAR:
Applications requesting $500,000 or more in direct costs for any year must
include a cover letter identifying the NIH staff member within one of NIH
institutes or centers who has agreed to accept assignment of the application.
Applicants requesting more than $500,000 must carry out the following steps:
1) Contact the IC program staff at least 6 weeks before submitting the
application, i.e., as you are developing plans for the study;
2) Obtain agreement from the IC staff that the IC will accept your
application for consideration for award; and,
3) Identify, in a cover letter sent with the application, the staff member
and IC who agreed to accept assignment of the application.
This policy applies to all investigator-initiated new (type 1), competing
continuation (type 2), competing supplement, or any amended or revised
version of these grant application types. Additional information on this
policy is available in the NIH Guide for Grants and Contracts, October 19,
2001 at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of
the application, including the checklist, and five signed photocopies in one
package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
The title, SLEEP DISTURBANCE IN PARKINSON'S DISEASE AND PARKINSON-LIKE
CONDITIONS, and the number of this announcement (PAS-03-131) must be typed on
line 2 of the face page of the application form and the YES box must be
checked.
APPLICATION PROCESSING: Applications must be mailed on or before the receipt
dates described at
http://grants.nih.gov/grants/funding/submissionschedule.htm. The CSR will
not accept any application in response to this PA that is essentially the
same as one currently pending initial review unless the applicant withdraws
the pending application. The CSR will not accept any application that is
essentially the same as one already reviewed. This does not preclude the
submission of a substantial revision of an application already reviewed, but
such application must include an Introduction addressing the previous
critique.
Although there is no immediate acknowledgement of the receipt of an
application, applicants are generally notified of the review and funding
assignment within 8 weeks.
PEER REVIEW PROCESS
Applications submitted for this PA will be assigned on the basis of
established PHS referral guidelines. An appropriate scientific review group
convened in accordance with the standard NIH peer review procedures
(http://www.csr.nih.gov/refrev.htm) will evaluate applications for scientific
and technical merit.
As part of the initial merit review, all applications will:
o Receive a written critique
o Undergo a selection process in which only those applications deemed to have
the highest scientific merit, generally the top half of applications under
review, will be discussed and assigned a priority score
o Receive a second level review by the appropriate national advisory council
or board
REVIEW CRITERIA
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health. In
the written comments, reviewers will be asked to discuss the following
aspects of the application in order to judge the likelihood that the proposed
research will have a substantial impact on the pursuit of these goals:
o Significance
o Approach
o Innovation
o Investigator
o Environment
The scientific review group will address and consider each of these criteria
in assigning the application's overall score, weighting them as appropriate
for each application. The application does not need to be strong in all
categories to be judged likely to have major scientific impact and thus
deserve a high priority score. For example, an investigator may propose to
carry out important work that by its nature is not innovative but is
essential to move a field forward.
SIGNIFICANCE: Does this study address an important problem? If the aims of
the application are achieved, how will scientific knowledge be advanced?
What will be the effect of these studies on the concepts or methods that
drive this field?
APPROACH: Are the conceptual framework, design, methods, and analyses
adequately developed, well-integrated, and appropriate to the aims of the
project? Does the applicant acknowledge potential problem areas and consider
alternative tactics?
INNOVATION: Does the project employ novel concepts, approaches or methods?
Are the aims original and innovative? Does the project challenge existing
paradigms or develop new methodologies or technologies?
INVESTIGATOR: Is the investigator appropriately trained and well suited to
carry out this work? Is the work proposed appropriate to the experience
level of the principal investigator and other researchers (if any)?
ENVIRONMENT: Does the scientific environment in which the work will be done
contribute to the probability of success? Do the proposed experiments take
advantage of unique features of the scientific environment or employ useful
collaborative arrangements? Is there evidence of institutional support?
ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, the following
items will be considered in the determination of scientific merit and the
priority score:
PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of human
subjects and protections from research risk relating to their participation
in the proposed research will be assessed. (See criteria included in the
section on Federal Citations, below).
INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy of
plans to include subjects from both genders, all racial and ethnic groups
(and subgroups), and children as appropriate for the scientific goals of the
research will be assessed. Plans for the recruitment and retention of
subjects will also be evaluated. (See Inclusion Criteria in the sections on
Federal Citations, below).
CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH: If vertebrate animals are to
be used in the project, the five items described under Section f of the PHS
398 research grant application instructions (rev. 5/2001) will be assessed.
ADDITIONAL CONSIDERATIONS
BUDGET: The reasonableness of the proposed budget and the requested period
of support in relation to the proposed research.
AWARD CRITERIA
Applications submitted in response to a PA will compete for available funds
with all other recommended applications. The following will be considered in
making funding decisions:
o Scientific merit of the proposed project as determined by peer review
o Availability of funds
o Relevance to program priorities
REQUIRED FEDERAL CITATIONS
HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that
applications and proposals involving human subjects must be evaluated with
reference to the risks to the subjects, the adequacy of protection against
these risks, the potential benefits of the research to the subjects and
others, and the importance of the knowledge gained or to be gained.
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm.
MONITORING PLAN AND DATA AND SAFETY MONITORING BOARD: Research components
involving Phase I and II clinical trials must include provisions for
assessment of patient eligibility and status, rigorous data management,
quality assurance, and auditing procedures. In addition, it is NIH policy
that all clinical trials require data and safety monitoring, with the method
and degree of monitoring being commensurate with the risks (NIH Policy for
Data and Safety Monitoring, NIH Guide for Grants and Contracts, June 12,
1998: http://grants.nih.gov/grants/guide/notice-files/not98-084.html).
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of
the NIH that women and members of minority groups and their sub-populations
must be included in all NIH-supported clinical research projects unless a
clear and compelling justification is provided indicating that inclusion is
inappropriate with respect to the health of the subjects or the purpose of the
research. This policy results from the NIH Revitalization Act of 1993 (Section
492B of Public Law 103-43).
All investigators proposing clinical research should read the "NIH Guidelines
for Inclusion of Women and Minorities as Subjects in Clinical Research -
Amended, October, 2001," published in the NIH Guide for Grants and Contracts
on October 9, 2001 (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-
02-001.html); a complete copy of the updated Guidelines are available at
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_
2001.htm. The amended policy incorporates: the use of an NIH definition
of clinical research; updated racial and ethnic categories in compliance with
the new OMB standards; clarification of language governing NIH-defined
Phase III clinical trials consistent with the new PHS Form 398; and updated
roles and responsibilities of NIH staff and the extramural community. The
policy continues to require for all NIH-defined Phase III clinical trials that:
a) all applications or proposals and/or protocols must provide a description
of plans to conduct analyses, as appropriate, to address differences by
sex/gender and/or racial/ethnic groups, including subgroups if applicable;
and b) investigators must report annual accrual and progress in conducting
analyses, as appropriate, by sex/gender and/or racial/ethnic group
differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS:
The NIH maintains a policy that children (i.e., individuals under the age of
21) must be included in all human subjects research, conducted or supported
by the NIH, unless there are scientific and ethical reasons not to include
them. This policy applies to all initial (Type 1) applications submitted for
receipt dates after October 1, 1998.
All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines" on the inclusion of children as participants in
research involving human subjects that is available at
http://grants.nih.gov/grants/funding/children/children.htm.
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH
policy requires education on the protection of human subject participants for
all investigators submitting NIH proposals for research involving human
subjects. You will find this policy announcement in the NIH Guide for Grants
and Contracts Announcement, dated June 5, 2000, at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The
Office of Management and Budget (OMB) Circular A-110 has been revised to
provide public access to research data through the Freedom of Information Act
(FOIA) under some circumstances. Data that are (1) first produced in a
project that is supported in whole or in part with Federal funds and (2)
cited publicly and officially by a Federal agency in support of an action
that has the force and effect of law (i.e., a regulation) may be accessed
through FOIA. It is important for applicants to understand the basic scope
of this amendment. NIH has provided guidance at
http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this PA in a public
archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application should
include a description of the archiving plan in the study design and include
information about this in the budget justification section of the
application. In addition, applicants should think about how to structure
informed consent statements and other human subjects procedures given the
potential for wider use of data collected under this award.
STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION: The
Department of Health and Human Services (DHHS) issued final modification to
the "Standards for Privacy of Individually Identifiable Health Information",
the "Privacy Rule," on August 14, 2002. The Privacy Rule is a federal
regulation under the Health Insurance Portability and Accountability Act
(HIPAA) of 1996 that governs the protection of individually identifiable
health information, and is administered and enforced by the DHHS Office for
Civil Rights (OCR). Those who must comply with the Privacy Rule (classified
under the Rule as "covered entities") must do so by April 14, 2003 (with the
exception of small health plans which have an extra year to comply).
Decisions about applicability and implementation of the Privacy Rule reside
with the researcher and his/her institution. The OCR website
(http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including
a complete Regulation Text and a set of decision tools on "Am I a covered
entity?" Information on the impact of the HIPAA Privacy Rule on NIH
processes involving the review, funding, and progress monitoring of grants,
cooperative agreements, and research contracts can be found at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals
for NIH funding must be self-contained within specified page limitations.
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs)
should not be used to provide information necessary to the review because
reviewers are under no obligation to view the Internet sites. Furthermore,
we caution reviewers that their anonymity may be compromised when they
directly access an Internet site.
HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to achieving
the health promotion and disease prevention objectives of "Healthy People
2010," a PHS-led national activity for setting priority areas. This RFA is
related to one or more of the priority areas. Potential applicants may obtain
a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
AUTHORITY AND REGULATIONS: This program is described in the Catalog of
Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review. Awards are made under the authorization of Sections
301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284)
and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All
awards are subject to the terms and conditions, cost principles, and other
considerations described in the NIH Grants Policy Statement. The NIH Grants
Policy Statement can be found at
http://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition,
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities (or in some cases, any portion of a facility) in which
regular or routine education, library, day care, health care, or early
childhood development services are provided to children. This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
|
|
|
Department of Health and Human Services (HHS)
|
|
|
|
NIH... Turning Discovery Into Health®
|